Clinical study evaluating salvage chemotherapy platinum and etoposide in refractory wilm's tumour

ABSTRACT

A total of 17 patients with refractory Wilm's tumor was included in this study who had received previous surgery, chemotherapy and/or radiotherapy to their primary disease. Site of recurrent disease was abdominal [local] in two patients, lung in four patients, liver in one patient and multiple in ten patients [local, lung, liver]. Cisplatin was given in a dose of 100 mg/m2 day 1 after proper hydration and etoposide in a dose of 100 mg/m2 days one-three. Cycles were repeated every 21 days and initial response was assessed after the 2nd cycle. The efficacy and/or toxicity of the drugs were evaluated during and after treatment. After initial assessment, only two patients attained complete response [CR], four patients had a partial response [PR], six patients had a stationary disease [SD] and five patients had progressive disease [PD]. At the end of the study, a total of 76 cycles was administered to 17 patients, the overall response rate [CR + PR] was 41.2% and the median follow up period was 8.9 months [range 4-20 months]. The combination was tolerable and chemotherapy had to be delayed for one week due to neutropenia on eight occasions of courses and no toxicity related deaths were recorded